סינגפור - אנגלית - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - acebutolol hcl eqv acebutolol - capsule - 100 mg

הממלכה המאוחדת - אנגלית - myHealthbox

lupin (europe) limited - gestodene - film-coated tablets - 20/75 microgram - hormonal contraceptives for systemic use, progestogens and estrogens, fixed combinations - oral contraception

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - rhinitis, allergic, seasonal - nasal preparations - symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.

קנדה - אנגלית - Health Canada

liberchem inc. - chlorhexidine acetate; alcohol anhydrous - wipe - 0.002%; 50% - chlorhexidine acetate 0.002%; alcohol anhydrous 50% - cattle

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bionpharma inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 1 ug - paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules should not be given to patients with evidence of - hypercalcemia or hypercalcemia or - vitamin d toxicity [see warnings and precautions ( 5.1) ]. vitamin d toxicity [see warnings and precautions ( 5.1) ]. risk summary limited data with paricalcitol capsules in pregnant women are insufficient to inform a drug‑associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenesis at doses 2 and 0.5 times, respectively, the maximum recommended human dose (mrhd). adverse reproductive outcomes were observed at doses that caused maternal toxicity [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk chronic kidney disease in pregnancy increases the maternal risk for hypertension, spontaneous abortion, preterm labor, and preeclampsia. chronic kidney disease increases the fetal risk for intrauterine growth restriction (iugr), prematurity, polyhydramnios, still birth, and low birth weight. data animal data pregnant rats and rabbits were treated with paricalcitol by once-daily intravenous (iv) injection during the period of organogenesis (in rats, from gestation day (gd) 6 to 17; in rabbits, from gd 6 to 18). rats were dosed at 0, 0.3, 1.0 or 3.0 mcg/kg/day and rabbits at 0, 0.03, 0.1 or 0.3 mcg/kg/day, representing up to 2 or 0.5 times, respectively, the maximum recommended human dose (mrhd) of 0.24 mcg/kg, based on body surface area (mg/m 2 ). slightly decreased fetal viability was observed in both studies at the highest doses representing 2 and 0.5 times, respectively, the mrhd in the presence of maternal toxicity (decreased body weight and food consumption). pregnant rats were administered paricalcitol by iv injection three times per week at doses of 0, 0.3, 3.0 or 20.0 mcg/kg/day throughout gestation, parturition and lactation (gd 6 to lactation day (ld) 20) representing exposures up to 13 times the mhrd. a small increase in stillbirths and pup deaths from parturition to ld 4 were observed at the high dose when compared to the control group (9.2% versus 3.3% in controls) at 13 times the mrhd, which occurred at a maternally toxic dose known to cause hypercalcemia in rats. surviving pups were not adversely affected; body weight gains, developmental landmarks, reflex ontogeny, learning indices, and locomotor activity were all within normal parameters. f1 reproductive capacity was unaffected. risk summary there is no information available on the presence of paricalcitol in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. studies in rats have shown that paricalcitol and/or its metabolites are present in the milk of lactating rats; however, due to specifies-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk [see data] . because of the potential for serious adverse reactions, including hypercalcemia in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with paricalcitol. data following a single oral administration of 20 mcg/kg of radioactive [ 3 h] paricalcitol to lactating rats, the concentrations of total radioactivity was determined. lower levels of total radioactivity were present in the milk compared to that in the plasma of the dams indicating that low levels of [ 3 h] paricalcitol and/or its metabolites are secreted into milk. exposure of the pups to [ 3 h] paricalcitol through milk was confirmed by the presence of radioactive material in the pups’ stomachs. safety and effectiveness of paricalcitol capsules in pediatric patients under the age of 10 years have not been established. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. of the total number (n = 220) of ckd stages 3 and 4 patients in clinical studies of paricalcitol capsules, 49% were age 65 and over, while 17% were age 75 and over. of the total number (n = 88) of ckd stage 5 patients in the pivotal study of paricalcitol capsules, 28% were age 65 and over, while 6% were age 75 and over. no overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bryant ranch prepack - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules should not be given to patients with evidence of - hypercalcemia or hypercalcemia or - vitamin d toxicity [see warnings and precautions ( 5.1) ]. vitamin d toxicity [see warnings and precautions ( 5.1) ]. risk summary limited data with paricalcitol capsules in pregnant women are insufficient to inform a drug‑associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenesis at doses 2 and 0.5 times, respectively, the maximum recommended human dose (mrhd). adverse reproductive outcomes were observed at doses that caused maternal toxicity [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk chronic kidney disease in pregnancy increases the maternal risk for hypertension, spontaneous abortion, preterm labor, and preeclampsia. chronic kidney disease increases the fetal risk for intrauterine growth restriction (iugr), prematurity, polyhydramnios, still birth, and low birth weight. data animal data pregnant rats and rabbits were treated with paricalcitol by once-daily intravenous (iv) injection during the period of organogenesis (in rats, from gestation day (gd) 6 to 17; in rabbits, from gd 6 to 18). rats were dosed at 0, 0.3, 1.0 or 3.0 mcg/kg/day and rabbits at 0, 0.03, 0.1 or 0.3 mcg/kg/day, representing up to 2 or 0.5 times, respectively, the maximum recommended human dose (mrhd) of 0.24 mcg/kg, based on body surface area (mg/m 2 ). slightly decreased fetal viability was observed in both studies at the highest doses representing 2 and 0.5 times, respectively, the mrhd in the presence of maternal toxicity (decreased body weight and food consumption). pregnant rats were administered paricalcitol by iv injection three times per week at doses of 0, 0.3, 3.0 or 20.0 mcg/kg/day throughout gestation, parturition and lactation (gd 6 to lactation day (ld) 20) representing exposures up to 13 times the mhrd. a small increase in stillbirths and pup deaths from parturition to ld 4 were observed at the high dose when compared to the control group (9.2% versus 3.3% in controls) at 13 times the mrhd, which occurred at a maternally toxic dose known to cause hypercalcemia in rats. surviving pups were not adversely affected; body weight gains, developmental landmarks, reflex ontogeny, learning indices, and locomotor activity were all within normal parameters. f1 reproductive capacity was unaffected. risk summary there is no information available on the presence of paricalcitol in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. studies in rats have shown that paricalcitol and/or its metabolites are present in the milk of lactating rats; however, due to specifies-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk [see data] . because of the potential for serious adverse reactions, including hypercalcemia in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with paricalcitol. data following a single oral administration of 20 mcg/kg of radioactive [ 3 h] paricalcitol to lactating rats, the concentrations of total radioactivity was determined. lower levels of total radioactivity were present in the milk compared to that in the plasma of the dams indicating that low levels of [ 3 h] paricalcitol and/or its metabolites are secreted into milk. exposure of the pups to [ 3 h] paricalcitol through milk was confirmed by the presence of radioactive material in the pups’ stomachs. safety and effectiveness of paricalcitol capsules in pediatric patients under the age of 10 years have not been established. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. of the total number (n = 220) of ckd stages 3 and 4 patients in clinical studies of paricalcitol capsules, 49% were age 65 and over, while 17% were age 75 and over. of the total number (n = 88) of ckd stage 5 patients in the pivotal study of paricalcitol capsules, 28% were age 65 and over, while 6% were age 75 and over. no overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

bryant ranch prepack - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stages 3 and 4. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with ckd stage 5 in patients on hemodialysis (hd) or peritoneal dialysis (pd). pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. paricalcitol capsules should not be given to patients with evidence of - hypercalcemia or hypercalcemia or - vitamin d toxicity [see warnings and precautions ( 5.1) ]. vitamin d toxicity [see warnings and precautions ( 5.1) ]. risk summary limited data with paricalcitol capsules in pregnant women are insufficient to inform a drug‑associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenesis at doses 2 and 0.5 times, respectively, the maximum recommended human dose (mrhd). adverse reproductive outcomes were observed at doses that caused maternal toxicity [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk chronic kidney disease in pregnancy increases the maternal risk for hypertension, spontaneous abortion, preterm labor, and preeclampsia. chronic kidney disease increases the fetal risk for intrauterine growth restriction (iugr), prematurity, polyhydramnios, still birth, and low birth weight. data animal data pregnant rats and rabbits were treated with paricalcitol by once-daily intravenous (iv) injection during the period of organogenesis (in rats, from gestation day (gd) 6 to 17; in rabbits, from gd 6 to 18). rats were dosed at 0, 0.3, 1.0 or 3.0 mcg/kg/day and rabbits at 0, 0.03, 0.1 or 0.3 mcg/kg/day, representing up to 2 or 0.5 times, respectively, the maximum recommended human dose (mrhd) of 0.24 mcg/kg, based on body surface area (mg/m 2 ). slightly decreased fetal viability was observed in both studies at the highest doses representing 2 and 0.5 times, respectively, the mrhd in the presence of maternal toxicity (decreased body weight and food consumption). pregnant rats were administered paricalcitol by iv injection three times per week at doses of 0, 0.3, 3.0 or 20.0 mcg/kg/day throughout gestation, parturition and lactation (gd 6 to lactation day (ld) 20) representing exposures up to 13 times the mhrd. a small increase in stillbirths and pup deaths from parturition to ld 4 were observed at the high dose when compared to the control group (9.2% versus 3.3% in controls) at 13 times the mrhd, which occurred at a maternally toxic dose known to cause hypercalcemia in rats. surviving pups were not adversely affected; body weight gains, developmental landmarks, reflex ontogeny, learning indices, and locomotor activity were all within normal parameters. f1 reproductive capacity was unaffected. risk summary there is no information available on the presence of paricalcitol in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. studies in rats have shown that paricalcitol and/or its metabolites are present in the milk of lactating rats; however, due to specifies-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk [see data] . because of the potential for serious adverse reactions, including hypercalcemia in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with paricalcitol. data following a single oral administration of 20 mcg/kg of radioactive [ 3 h] paricalcitol to lactating rats, the concentrations of total radioactivity was determined. lower levels of total radioactivity were present in the milk compared to that in the plasma of the dams indicating that low levels of [ 3 h] paricalcitol and/or its metabolites are secreted into milk. exposure of the pups to [ 3 h] paricalcitol through milk was confirmed by the presence of radioactive material in the pups’ stomachs. safety and effectiveness of paricalcitol capsules in pediatric patients under the age of 10 years have not been established. pediatric use information for patients 10 to 16 years of age is approved for abbvie inc.’s zemplar (paricalcitol) capsules. however, due to abbvie inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. of the total number (n = 220) of ckd stages 3 and 4 patients in clinical studies of paricalcitol capsules, 49% were age 65 and over, while 17% were age 75 and over. of the total number (n = 88) of ckd stage 5 patients in the pivotal study of paricalcitol capsules, 28% were age 65 and over, while 6% were age 75 and over. no overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

דרום אפריקה - אנגלית - South African Health Products Regulatory Authority (SAHPRA)

servier -